Ablynx

Ablynx Overview

Founded 2001
Founded
Status Acquired/​Merged
Employees 438
Employees
Latest Deal Type M&A
Latest Deal Amount $4.56B
Latest Deal Amount

Ablynx General Information

Description

Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, hematology, immuno-oncology, oncology and respiratory diseases. The company's biopharmaceutical products comprises of their patented product named, Nanobodies that is a therapeutic proteins based on single-chain antibody fragments that combine the benefits of drugs based on conventional antibodies and small chemical molecules, enabling patients avail various therapeutic and new drugs that can make a clear difference to society.

Contact Information

Website
Formerly Known As
MatchX
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • Technologiepark 21
  • 9052 Ghent
  • Belgium
+32 09 000 00 00

Ablynx Timeline

20172018
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ablynx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 19-Jun-2018 $4.56B 00000 00.000 Completed Profitable
12. Merger/Acquisition 01-Dec-2017 00.000 00.000 Cancelled Profitable
11. PIPE 04-Oct-2017 00000 Completed Profitable
10. Secondary Transaction - Open Market 03-Nov-2016 00000 Completed Profitable
9. PIPE 01-Jun-2016 000.00 00000 Completed Profitable
8. Secondary Transaction - Open Market 18-Oct-2013 00.000 00000 Completed Generating Revenue
7. 2PO 16-Mar-2010 000.00 00000 Completed Generating Revenue
6. IPO 07-Nov-2007 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 23-Aug-2006 $51.2M $88.2M Completed Generating Revenue
4. Early Stage VC (Series B) 06-Apr-2004 $30.5M $37M Completed Generating Revenue

Ablynx Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Lixte Biotechnology Holdings Corporation East Setauket, NY 0
00000 Venture Capital-Backed Cambridge, United Kingdom 000 00000 0000000000 0 00000
0000000 0000000000 Formerly VC-backed Newark, CA 00 00000 00000000 00000
000000 Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 000000000000 00000

Ablynx Executive Team (17)

Name Title Board Seat Contact Info
Wim Ottevaere Chief Financial Officer
Piet Houwen Chief Operating Officer
Robert Friesen Ph.D Chief Scientific Officer
Ludo Haazen MD Medical & Clinical Research Consultant
Russell Greig Ph.D Independent Director

9 Former Executives

Ablynx Board Members (9)

To view Ablynx‘s full board member team, request access >>
Name Representing Role Since
Catherine Moukheibir Self Independent Director & Board Member 000 0000
Geert Cauwenbergh Ph.D Self Board Member 000 0000
Remi Vermeiren Self Board Member 000 0000
Roger Perlmutter Ph.D Self Board Member 000 0000

5 Former Board Members

Ablynx Former Investors (10)

To view Ablynx‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Management Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
Fidelity Management & Research Asset Manager Minority 000 0000 000000 0
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0

Ready to get started?

Request a free trial